TB-500 is a synthetic peptide corresponding to the actin-binding domain of thymosin beta-4 (Tβ4) — specifically amino acids 17–23 (LKKTETQ). Thymosin beta-4 itself is a 43-amino acid protein abundant in platelets and wound fluid, where it plays a central role in cytoskeletal organization, cell migration, and tissue repair. TB-500's active fragment retains the key biological functions of the parent protein in a more stable and bioavailable form.
Thymosin Beta-4 Biology
Thymosin beta-4 was first isolated from thymus tissue and initially studied as a thymic hormone. Subsequent research revealed it is one of the most abundant intracellular peptides in mammalian cells — found at highest concentrations in platelets and wound fluid.
Its primary cellular function is actin sequestration: Tβ4 binds G-actin (globular actin monomers) and maintains a pool of actin available for rapid polymerization when cells need to migrate or change shape. This makes it essential for: - Cell migration (fundamental to wound healing) - Angiogenesis (new vessel formation requires endothelial cell migration) - Tissue repair and remodeling
Mechanism of Action
Actin Sequestration: TB-500's LKKTETQ sequence is the critical actin-binding domain. By modulating G-actin availability, it promotes cytoskeletal dynamics and cell motility.
Upregulation of Cell Surface Receptors: Tβ4 and TB-500 have been shown to upregulate expression of integrins and growth factor receptors on cell surfaces, promoting cellular response to injury signals.
Anti-inflammatory effects: TB-500 downregulates inflammatory cytokines including IL-6 and TNF-α in models of acute inflammation. It also reduces NF-κB activation in damaged tissue.
Promotion of Stem Cell Migration: Studies have shown Tβ4 promotes migration of stem and progenitor cells to sites of injury — potentially accelerating endogenous repair processes.
Research Findings by Tissue Type
Cardiac: Some of the most compelling Tβ4 research is in cardiac biology. Studies have shown cardiac progenitor cell activation and migration following MI in Tβ4-treated animals. Epicardial cells that normally remain quiescent can be induced to migrate and differentiate toward cardiomyocytes by Tβ4.
Musculoskeletal: In rodent models of muscle injury, tendon damage, and ligament repair, TB-500 administration has accelerated histological healing and functional recovery. It is often studied alongside BPC-157 for synergistic effects.
Corneal/Ocular: Tβ4 is in clinical trials for dry eye disease and has shown efficacy in corneal wound healing — one of the more advanced clinical applications of Tβ4 biology.
Neurological: Early-stage research has examined Tβ4's role in neuronal migration and nerve regeneration following injury.
TB-500 vs. Full Thymosin Beta-4
TB-500 (the LKKTETQ fragment) is sometimes preferred in research for its: - Smaller size → potentially better bioavailability and tissue penetration - Focused activity on the actin-binding mechanism - Lower cost of synthesis
However, full Tβ4 has additional functional domains not present in TB-500, including sequences involved in T-cell differentiation and some anti-apoptotic effects. Researchers should consider which aspects of Tβ4 biology are most relevant to their model.
Published References
Research Use Only. All content is for informational and educational purposes regarding preclinical research. None of the compounds discussed have been approved by the FDA for human therapeutic use. This information does not constitute medical advice.
Peptide Storage & Handling Best Practices
5 min readKPV: The Anti-Inflammatory Tripeptide
7 min read